Search for: "SCHERING-PLOUGH"
Results 221 - 240
of 404
Sort by Relevance
|
Sort by Date
6 Aug 2009, 8:40 am
And apparently, about 140 claimants could just imagine the execs at Merck and Schering-Plough humming along, as they buried (for about two years) an unfavorable study that showed the companies' jointly marketed cholesterol drugs, Vytorin and Zetia "were no more effective in unclogging arteries than a pre-existing and less expensive cholesterol treatment[s]. [read post]
5 Aug 2009, 12:50 pm
She cites a number of isolated examples of drug ad distraction: · An ad for Schering-Plough’s allergy drug Nasonex featured a bumble bee that flew around as side effects were listed, but simply hovered when benefits were discussed. [read post]
4 Aug 2009, 1:15 am
Merck, which is buying rival Schering-Plough Corp., had a reserve of about $24 million for the litigation, including lawyers' fees, as of March 31, having spent $9 million on the cases in the first quarter, the company said in May. [read post]
30 Jul 2009, 7:02 am
The same Bloomberg article also re-caps the most recent (albeit a bit dated) information about the extent of this ongoing Fosamax litigation: Merck, which is buying rival Schering-Plough Corp., had a reserve of about $24 million for the litigation, including lawyers' fees, as of March 31, having spent $9 million on the cases in the first quarter, the company said in May. [read post]
23 Jul 2009, 3:15 am
We wouldn't base a motion solely on Actimmune, but with Pennsylvania Employees as the lead case, Actimmune is useful supporting precedent.Another candidate for best supporting actor in this area is In re Schering-Plough Corp. [read post]
22 Jul 2009, 12:32 pm
In fact, a 2007 piece in the New York Times suggested that Merck and Schering-Plough may have also suppressed evidence from clinical trials that found a connection between the drugs and liver problems. [read post]
20 Jul 2009, 10:34 am
Article in AmLaw Litigation Daily -- Schering-Plough Wins Dismissal of 'Off-Label' Suit, by Ben Hallman. [read post]
13 Jul 2009, 9:28 pm
A tip of the old cyberhat - and not for the first time - to Alan Modlinger at Lowenstein Sandler for passing along to us the latest good news on the off-label promotion front - dismissal (with leave to replead under Twombly) in In re Schering-Plough Corp. [read post]
25 Jun 2009, 4:29 am
This post is largely about drug and medical device litigation "inside baseball. [read post]
23 Jun 2009, 9:10 am
Schering Plough paid a $500 million fine for manufacturing violations and $345 million for improper marketing of Claritin, an allergy drug, Rost says. [read post]
22 Jun 2009, 6:23 am
The nation's antitrust regulators want more information about Merck's plan to buy Schering-Plough, a $46 billion transaction that is one of the biggest to be announced so far this year. [read post]
17 Jun 2009, 7:59 am
Yesterday, Schering-Plough (SGP) filed this amended S-4, updating information in their May 20 filing (which we footnoted here). [read post]
12 Jun 2009, 12:10 pm
., Schering-Plough Corp. v. [read post]
10 Jun 2009, 6:05 am
Zambri, Esquire and Catherine Bertram, Esquire Bloomberg News reports that "Merck & Co. and Schering-Plough Corp. were sued by a Pennsylvania fund for active and retired state employees over claims they misled consumers into paying too much for prescriptions of Zetia [ezetimibe] and Vytorin cholesterol pills. [read post]
29 May 2009, 4:58 am
Soliciting Shareholder Feedback on Compensation Practices - Taking a page from Schering-Plough's efforts to survey investors about pay practices, Amgen is inviting its shareholders to offer comments on TIAA-CREF's "Ten Questions for Evaluating CD&As. [read post]
26 May 2009, 9:54 am
The companies agreeing to the Alabama settlement are: Abbott Laboratories, Schering-Plough Corp., Warrick Pharmaceuticals Corp., TEVA Pharmaceuticals USA, IVAX Corp., IVAX Pharmaceuticals, Barr Laboratories, Aventis Pharmaceuticals, Aventis Behring, ZLB Behring, Sanofi-Synthelabo, Forest Laboratories, Forest Pharmaceuticals, Baxter Healthcare Corp. and Baxter International. [read post]
21 May 2009, 7:08 am
In the S-4 that Schering-Plough filed late yesterday they say this about Company X: Also during the January 9, 2009 Schering-Plough board update, Schering-Plough's financial advisors noted that another company ("Company X") potentially had the financial and operational capacity to complete a strategic transaction with Schering-Plough and that, other than Merck, Company X was, in their view, the entity most likely… [read post]
13 May 2009, 8:41 am
If I remember correctly, most of Pharmacia's old management went to Schering-Plough. [read post]
10 May 2009, 7:29 pm
" Allowing preferred clients access to work product, showing value delivered beyond the services provided, and honing knowledge capital to a discloseable level of quality, certainly both distinguishes a law firm and benefits a law department (See my post of March 9, 2007: direct access to knowledge base of law firms; and May 17, 2006: Schering-Plough expected its central firms to share work product.). [read post]
6 May 2009, 4:49 pm
Schering-Plough Corp. [read post]
